Overcoming endocrine resistance in breast cancer

R A Madaio1, G Spalletta, L Cravello

  • 1Division of Medical Oncology, Ospedale Israelitico, Rome, Italy.

Insights

Estrogen receptor-positive breast cancer often becomes resistant to endocrine therapy. This review covers molecular mechanisms of resistance and highlights strategies to overcome it in hormone-responsive breast cancer.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Estrogen receptor (ER)-positive breast cancer accounts for approximately 70% of all breast cancers.
  • Endocrine therapy is a cornerstone of treatment for hormone-responsive breast cancer.
  • Endocrine resistance, intrinsic or acquired, affects up to 25% of ER-positive breast cancers.

Purpose of the Study:

  • To review molecular mechanisms underlying intrinsic and acquired endocrine resistance in ER-positive breast cancer.
  • To highlight promising therapeutic strategies for overcoming endocrine resistance.

Main Methods:

  • Literature review of molecular mechanisms of endocrine resistance.
  • Analysis of current and emerging strategies to combat endocrine resistance.

Main Results:

  • Multiple molecular mechanisms contribute to both de novo and acquired endocrine resistance.
  • Various therapeutic strategies show promise in preclinical and clinical settings.

Conclusions:

  • Understanding resistance mechanisms is crucial for developing effective treatments.
  • Targeting specific pathways offers potential to overcome endocrine resistance in breast cancer patients.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...